GRADE: 15-valent pneumococcal conjugate vaccine (PCV15) use in children aged <2 years
MMWR recomm. rep
; 71(37): 1-5, 20220916. tab
Artículo
en Inglés
| BIGG - guías GRADE
| ID: biblio-1512323
Biblioteca responsable:
BR1.1
ABSTRACT
On June 22, 2022, ACIP recommended use of 15-valent pneumococcal conjugate vaccine (PCV15 [Vaxneuvance, Merck Sharp & Dohme LLC]) as an option for pneumococcal conjugate vaccination for persons aged <19 years according to currently recommended PCV13 dosing and schedules. A systematic review and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach was employed to guide ACIP's deliberations regarding use of this vaccine.
C - All Rights Reserved
Asunto(s)
Texto completo:
Disponible
Colección:
Bases de datos temática
Base de datos:
BIGG - guías GRADE
Asunto principal:
Infecciones Neumocócicas
/
Vacuna Neumocócica Conjugada Heptavalente
/
Inmunogenicidad Vacunal
Idioma:
Inglés
Revista:
MMWR recomm. rep
Año:
2022
Tipo del documento:
Artículo
